• Active Substance: Venetoclax
  • Name: Venclyxto
  • Therapeutic area: Acute myeloid leukaemia (AML)
  • Pharmaceutical company: AbbVie GmbH & Co. KG


Time table:

  • Publication of project plan: 28.04.2021
  • Publication of final assessment: 08.07.2021 (revised 03.09.2021)


Assessment information:

  • Title: Venetoclax with a hypomethylating agent or low-dose cytarabine for the treatment of adult patients with newly-diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy
  • Author/Co-Author: NOMA (Norway), JAZMP (Slovenia)
  • Dedicated Reviewers: AEMPS (Spain), NIPHNO (Norway), MoH (Ukraine), SMCA (Lithuania)